English name: Crizotinib
Drug Category:Other antineoplastic agents [otw_shortcode_tabslayout tabs=”9″ tab_1_title=”Overview” tab_1_content=”Crizotinib is an antineoplastic agent. It is used for the treatment of patients with localized Japanese or metastatic non-small cell lung cancer (NSCLC) who are positive for mesenchymal lymphoma kinase (ALK) as determined by a CFDA-approved assay.” tab_2_title=”Indications” tab_2_content=”Non-small cell lung cancer” tab_3_title=”Dosage” tab_3_content=”The dosage varies when the drug is used to treat different indications. The dosage form used is capsules. This is a prescription drug. Please read the instructions carefully and use under the guidance of a physician. The recommended dose of crizotinib capsules for patients with non-small cell lung cancer (NSCLC) is 250 mg orally twice daily until the disease progresses or is intolerable to the patient. For patients with severe renal impairment (creatinine clearance less than 30 ml/min) who do not require dialysis, the recommended dose of crizotinib capsules is 250 mg orally once daily. Capsules should be swallowed whole. Dosing tips If the effect of the medication does not meet your expectations, please consult your doctor or pharmacist and do not increase the dose yourself if possible; overdose may lead to serious consequences. If you miss a dose, please do not take it at your own discretion and consult your doctor or pharmacist if necessary. If you miss a dose of crizotinib capsules, take the missed dose unless it is less than 6 hours before your next dose. If you vomit after taking a dose, take the next dose at the normal time. Follow your doctor’s instructions for dose adjustment.” tab_4_title=”Precautions” tab_4_content=”If you are a woman of childbearing potential, you should use effective contraception during and for at least 45 days after you stop taking the drug. If you are a male patient with a female (fertile) partner, you should use condoms during and for at least 90 days after discontinuation. Increase or decrease discontinuation: how to increase or decrease the dose and how to discontinue If you develop new onset of severe vision loss (best corrected visual acuity below 20/200 in one or both eyes) while on the drug, discontinue the drug and have an ophthalmologic evaluation and decide whether to reintroduce the drug after weighing the pros and cons based on the results of the evaluation.” tab_5_title=”Contraindications” tab_5_content=”Contraindicated if you are: allergic to the drug. Severe hepatic impairment.” tab_6_title=”Adverse reactions” tab_6_content=”In addition to treating your disease, the drug may also cause you some discomfort during the course of use. Some of the adverse reactions may disappear in the course of drug use. When you encounter adverse reactions that affect your life, you should promptly communicate with your doctor and pharmacist. Possible adverse reactions: Common: visual abnormalities, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue. Rare: neutropenia, thrombocytopenia, etc. Warnings: serious adverse reactions such as hepatotoxicity, interstitial lung disease (non-infectious pneumonia), prolonged QT interval, bradycardia, neutropenia and leukopenia, embryotoxicity, and gastrointestinal perforation.” tab_7_title=”Interactions” tab_7_content=”Drugs can be affected by food, other drugs taken at the same time, as they take effect in the body or are metabolized out of the body. Some effects may enhance or diminish the effectiveness of the drug. Some effects may also cause you to have adverse drug reactions and should therefore be noted. Foods that may affect the drug: Grapefruit juice. Grapefruit juice may increase the blood level of this drug. Avoid combining. High-fat meals. High-fat meals may reduce the area under the curve and peak blood concentration of this drug by about 14%. This drug may or may not be taken with food. Other drugs that may affect this drug: Potent cytochrome P450 (CYP) 3A inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, vinblastomycin, voriconazole), may increase the blood concentration of this drug in combination. Avoid co-administration. Combination of CYP 3A substrates with a narrow therapeutic window (e.g. alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) may alter the blood concentrations of these drugs. This drug can inhibit CYP 3A. If combined use is necessary, the dose of these drugs may need to be reduced. Combination of potent CYP 3A inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. John’s wort) may reduce blood levels of this drug. Avoid combining.” tab_8_title=”Special Populations” tab_8_content=”Pregnant/Nursing Elderly Infants Other ” tab_9_title=”Other” tab_9_content=”Drug properties Crizotinib: capsules with white to light yellow powder contents. Common specifications Crizotinib capsules: 250mg; 200mg. Reference price $13000.00 – $15000.00 Storage method Store below 30°C.”] [/otw_shortcode_tabslayout]